Get Your Personalized Supplement StackSupplement Stack Quiz

Leuconostoc Cremoris

Also known as: Leuconostoc cremoris, L. cremoris, Leuconostoc mesenteroides subsp. cremoris

Overview

Leuconostoc cremoris is a subspecies of Leuconostoc mesenteroides, belonging to the lactic acid bacteria (LAB) group. It is commonly found in various fermented foods, including dairy products, dough, and vegetables. As a heterofermentative bacterium, L. cremoris produces lactic acid, ethanol, and carbon dioxide during glucose metabolism. It is utilized as a probiotic to support gut health and prevent antibiotic-associated diarrhea. Research indicates that L. cremoris possesses the ability to resist bile and adhere to mucosal surfaces, contributing to its probiotic effects. Genomic and metabolic studies have provided substantial insights into its characteristics, although further clinical trials are necessary to fully validate its efficacy and safety across diverse applications. Its role in producing bioactive compounds further enhances its potential health-promoting properties.

Benefits

Leuconostoc cremoris, as a probiotic, offers several potential health benefits, primarily related to gut health and immune support. While specific studies focusing solely on L. cremoris are limited, research on probiotics in general suggests its efficacy in restoring gut microbiota and preventing antibiotic-associated diarrhea, particularly in children. Systematic reviews indicate that co-administration of probiotics with antibiotics can reduce the incidence of diarrhea. Additionally, L. cremoris can produce bioactive compounds with antimicrobial properties, further contributing to its health-promoting effects. The benefits from probiotic supplementation can typically be observed within a few days to weeks of administration, especially during antibiotic use.

How it works

Leuconostoc cremoris exerts its probiotic effects through several mechanisms. Primarily, it colonizes the gut, contributing to a balanced gut microbiota by producing lactic acid and other beneficial metabolites. These metabolites help maintain a healthy gut environment, inhibiting the growth of pathogenic bacteria. Additionally, L. cremoris adheres to the mucosal surfaces of the gastrointestinal tract, preventing the colonization of harmful pathogens. By interacting with the gastrointestinal system, it influences both gut microbiota composition and immune function, modulating the immune response and promoting overall gut health.

Side effects

Leuconostoc cremoris is generally considered safe for consumption, especially when obtained from fermented foods or probiotic supplements. Common side effects are rare, but some individuals may experience mild gastrointestinal symptoms such as bloating or gas. Uncommon side effects, occurring in 1-5% of users, may include allergic reactions or exacerbation of underlying gastrointestinal conditions. In rare cases, probiotics can cause infections in immunocompromised individuals, necessitating caution in this population. While significant drug interactions are not commonly reported, caution is advised when used in conjunction with immunosuppressive drugs. Pregnant or breastfeeding women should consult healthcare providers before using probiotic supplements containing L. cremoris.

Dosage

While a minimum effective dose for Leuconostoc cremoris specifically is not definitively established, typical probiotic dosages range from 1 to 10 billion CFU (Colony-Forming Units) per day. For general probiotic use, this dosage range is commonly recommended. A maximum safe dose has not been established, but exceeding recommended dosages is generally unnecessary. It is best taken with meals to enhance survival through the stomach's acidic environment. L. cremoris is available in various forms, including capsules, tablets, and powders; selecting a form that ensures the viability of the bacteria is crucial. As L. cremoris acts locally in the gut, absorption factors are not applicable, but a balanced diet supports overall gut health.

FAQs

How long does it take to see benefits?

Benefits from Leuconostoc cremoris can typically be observed within a few days to weeks of consistent use, particularly in the context of antibiotic use or gut health improvement.

Are there any interactions with medications?

Generally, no significant interactions are reported, but caution is advised when using immunosuppressive drugs concurrently. Consult a healthcare provider for personalized advice.

Is it safe for immunocompromised individuals?

Immunocompromised individuals should use Leuconostoc cremoris with caution and under medical supervision due to the potential risk of infection.

What are the common side effects?

Common side effects are generally rare, but some individuals may experience mild gastrointestinal symptoms such as bloating or gas when starting supplementation.

When is the best time to take it?

It is best taken with meals to enhance the survival of the bacteria through the stomach's acidic environment, promoting better colonization in the gut.

Research Sources

https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.897656/full – This phylogenomic analysis of Leuconostoc species, including L. cremoris, examined 216 genome sequences. The study found that L. cremoris is a subspecies of L. mesenteroides with high genetic similarity among strains, indicating a close evolutionary relationship. This research provides a foundation for understanding the genetic diversity and classification within the Leuconostoc genus.
https://www.researchgate.net/publication/332784217_Probiotics_for_the_prevention_of_pediatric_antibiotic-associated_diarrhea – This systematic review assessed the efficacy of probiotics, including Leuconostoc species, in preventing antibiotic-associated diarrhea in children. The review analyzed various clinical trials and found that probiotics can reduce the incidence of diarrhea in pediatric populations undergoing antibiotic treatment. While specific data on L. cremoris is limited, the findings support the use of probiotics in managing antibiotic-associated diarrhea in children.
https://www.biorxiv.org/content/10.1101/2021.06.20.449192v1.full – This integrative genomic and metabolic analysis examined six representative LAB strains, including Leuconostoc, to evaluate genome-wide metabolic landscapes. The study revealed that Leuconostoc species possess unique metabolic capabilities, including the production of bioactive compounds and antimicrobial substances. These findings highlight the potential health-promoting properties of Leuconostoc through its metabolic activities.
https://pubmed.ncbi.nlm.nih.gov/23495911/ – This study investigates the use of probiotics for treating acute gastroenteritis in children. It concludes that certain probiotic strains can reduce the duration and severity of symptoms. While it doesn't focus specifically on Leuconostoc Cremoris, it provides context for the broader use of probiotics in pediatric gastrointestinal health.